Head-to-head evidence
Savolitinib vs Tepotinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: MET · full Non-Small Cell Lung Cancer pipeline
Savolitinib · Orpathys
Marketed by AstraZeneca and partners
NCT05015608 · Phase 3 · completed
The trial randomized 216 participants to savolitinib plus osimertinib or active chemotherapy, but treatment was not blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT04322890 (registry estimate)
Tepotinib · Tepmetko
Marketed by Merck KGaA and partners
NCT02864992 · Phase 2 · active, not recruiting
An open-label, single-arm Phase 2 study with no comparator arm; objective response was assessed by blinded independent review. The response rate (46% in 99 patients with at least 9 months of follow-up) supported FDA accelerated approval, but without a control group the study cannot separate the drug's effect from the course of the disease.
Next expected readout: December 2027 · NCT06083857 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Savolitinib's landscape · Tepotinib's landscape